Views & Analysis The EMA’s Adaptive Pathways: are safety concerns exaggerated... Companies still need to provide a compelling case for efficacy
News Samsung Bioepis' Remicade rival approved in EU Merck, Sharp and Dohme's (MSD) inflammatory diseases blockbuster Remicade (infliximab) faces further biosimilar competition after Samsung Bioepis' rival, Flixabi, was approved in Europe.
News UK needs 'clearer path for dementia diagnosis and treatment' UK Prime Minister Andy Burnham, who lost his father to Alzheimer's last week, has been urged to implement a "cancer-style" reform of dementia care.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
